Literature DB >> 15485599

Antihypertensive drugs and the heart.

Joseph A Diamond1, Robert A Phillips.   

Abstract

Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are early signs of cardiac end-organ damage (hypertensive heart disease) in patients with arterial hypertension. The presence of LVH or CHF-D confers increased risk of cardiovascular morbidity and mortality in patients with hypertension. Regression of left ventricular mass with antihypertensive therapy is associated with reduction in cardiovascular events. Antihypertensive therapy should be geared to both lower blood pressure and specifically reverse the pathophysiologic processes that may be independent of actual blood pressure. This review summarizes current and emerging approaches to the treatment of individuals with hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485599     DOI: 10.1007/s11886-004-0047-2

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  56 in total

1.  Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  J S Gottdiener; D J Reda; B M Massie; B J Materson; D W Williams; R J Anderson
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

Review 2.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

3.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

4.  Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense.

Authors:  B Kimura; D Mohuczy; X Tang; M I Phillips
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

5.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

6.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.

Authors:  J F Setaro; B L Zaret; D S Schulman; H R Black; R Soufer
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

7.  The pathogenesis of acute pulmonary edema associated with hypertension.

Authors:  S K Gandhi; J C Powers; A M Nomeir; K Fowle; D W Kitzman; K M Rankin; W C Little
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

8.  Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.

Authors:  M L Muiesan; M Salvetti; D Rizzoni; M Castellano; F Donato; E Agabiti-Rosei
Journal:  J Hypertens       Date:  1995-10       Impact factor: 4.844

9.  Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.

Authors:  Takehiro Ogata; Takashi Miyauchi; Satoshi Sakai; Masakatsu Takanashi; Yoko Irukayama-Tomobe; Iwao Yamaguchi
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

Review 10.  Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure.

Authors:  M Packer
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.